Home » Newsletters » BioWorld Science

BioWorld Science

March 19, 2013

View Archived Issues

Receptos licenses RPC-4046 from AbbVie

NAT2 study finds prevention of exudative age-related macular degeneration with DHA/EPA

Modified western blot assay detects Plasmodium circumsporozoite protein

Personal Genome Diagnostics licenses rights to genome mapping technology

ANAVEX 2-73 protects against Abeta25-35 toxicity in Alzheimer's disease mouse models

Biomaterial for prevention of heart failure found safe, effective in preclinical studies

OG-L002 helps demonstrate role of LSD1 in regulation of HSV infection

Improved tolerability of tolterodine/pilocarpine fixed-dose combination without loss of efficacy

Japanese scientists divulge novel PDE10A inhibitors

Hyperuricemia therapy patented by Kissei Pharmaceutical

Novel antipsychotic drugs reported by Merck & Co.

Trimel reports pivotal phase III data for CompleoTRT

Novel O-GlcNAcase inhibitors disclosed in Germany

Novo Nordisk reports data from phase IIIa liraglutide study

Long-term fingolimod treatment of relapsing-remitting MS proven safe in FREEDOMS II extension study

MethylGene reports data from phase II MGCD-290 trial

PI3K inhibitors disclosed by GlaxoSmithKline

FDA grants orphan drug status to a recombinant fusion protein and an AAV-G6Pase vector

Alnylam begins phase I ALN-TTRsc trial in TTR-mediated amyloidosis

Virobay and LEO Pharma begin phase I trial of VBY-891

Supplemental BLA submitted to expand Adcetris use in U.S.

Pegasys receives E.U. approval for HCV in children 5 years of age and older

Regen BioPharma receives FDA IND number for HemaXellerate

Bioradar targets Replikin increase in antibiotic-resistant bacterial strains, in vaccine strategy

FDA clears Quidel and Life Technologies products

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...